Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

NCT05013216 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

High Risk Cancer
Pancreatic Cancer

Interventions

DRUG: Cohort A: Patients at high risk of developing pancreatic cancer.
DRUG: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]